Healthcare -
Biotechnology - NASDAQ - US
$ 17.78
-3.94 %
$ 545 M
Market Cap
-3.47
P/E
1. INTRINSIC VALUE
Balance Sheet
AnaptysBio, Inc.
| Current Assets | 432 M |
| Cash & Short-Term Investments | 385 M |
| Receivables | 40.8 M |
| Other Current Assets | 5.74 M |
| Non-Current Assets | 52 M |
| Long-Term Investments | 35.5 M |
| PP&E | 16.2 M |
| Other Non-Current Assets | 256 K |
| Current Liabilities | 45.4 M |
| Accounts Payable | 4 M |
| Short-Term Debt | 1.92 M |
| Other Current Liabilities | 39.5 M |
| Non-Current Liabilities | 368 M |
| Long-Term Debt | 14.1 M |
| Other Non-Current Liabilities | 353 M |
EFFICIENCY
Earnings Waterfall
AnaptysBio, Inc.
| Revenue | 91.3 M |
| Cost Of Revenue | 0 |
| Gross Profit | 91.3 M |
| Operating Expenses | 206 M |
| Operating Income | -115 M |
| Other Expenses | 30.3 M |
| Net Income | -145 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
AnaptysBio, Inc.
| Net Income | -145 M |
| Depreciation & Amortization | 2.4 M |
| Capital Expenditures | -358 K |
| Stock-Based Compensation | 34 M |
| Change in Working Capital | 0 |
| Others | -26.6 M |
| Free Cash Flow | -136 M |
Wall Street Analysts Price Targets
AnaptysBio, Inc.
Wall Street analysts predict an average 1-year price target for ANAB of $47.5 , with forecasts ranging from
a
low of
$19 to a high of $90 .
ANAB Lowest Price Target
Wall Street Target
19 USD
6.86%
ANAB Average Price Target
Wall Street Target
47.5 USD
167.15%
ANAB Highest Price Target
Wall Street Target
90 USD
406.19%
4. DIVIDEND
ANALYSIS
ANAB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
AnaptysBio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
250 K USD 1
6-9 MONTHS
1.56 M USD 4
9-12 MONTHS
126 K USD 3
Bought
0 USD 0
0-3 MONTHS
1.1 M USD 1
3-6 MONTHS
10 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
zacks.com
- 2 weeks ago
Anaptys Announces Stock Repurchase Plan
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share.
globenewswire.com
- 2 weeks ago
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.
zacks.com
- 1 month ago
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$420 million and reiterating cash runway through year-end 2027 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “Rosnilimab's positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy data that was sustained and surpasses six-month data from competitor all-active, head-to-head trials.
globenewswire.com
- 1 month ago
Anaptys Announces Participation in March Investor Conferences
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 4, 2025 at 1:10pm ET / 10:10am PT Leerink Partners 2025 Global Healthcare Conference, Miami, FL Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 11, 2025 at 10:40am ET / 7:40am PT Barclays 27 th Annual Global Healthcare Conference, Miami, FL Format – Presentation and one-on-one investor meetings Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
globenewswire.com
- 1 month ago
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
zacks.com
- 1 month ago
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs and reduction of CRP across all doses Rosnilimab was safe and well tolerated with similar adverse event rates vs.
globenewswire.com
- 1 month ago
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
globenewswire.com
- 2 months ago
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.
globenewswire.com
- 2 months ago
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply Anaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines.
prnewswire.com
- 2 months ago
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP).
globenewswire.com
- 2 months ago
8. Profile
Summary
AnaptysBio, Inc. ANAB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 545 M
Dividend Yield
0.00%
Description
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Contact
10770 Wateridge Circle, San Diego, CA, 92121-5801
https://www.anaptysbio.com
IPO
Date
Jan. 26, 2017
Employees
136
Officers
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.
Chief Medical Officer
Mr. Dennis M. Mulroy
Chief Financial Officer
Mr. Daniel R. Faga
President, Chief Executive Officer & Director
Dr. Martin Dahl Ph.D.
Senior Vice President of Research
Ms. Beth Mueller
Senior Vice President of Human Resources
Mr. Benjamin Stone
Chief Business Officer
Mr. Douglas A. Rich M.B.A.
Senior Vice President of CMC
Mr. Eric J. Loumeau
Chief Legal Officer
Ms. Monique Da Silva
Senior Vice President of Corporate Affairs
Ms. Priya Raina
Senior Vice President of Clinical Operations